Arrowhead Pharmaceuticals's total assets for Q2 2026 were $2.27B, an increase of 41.40% from the previous quarter. ARWR total liabilities were $1.67B for the fiscal quarter, a 60.29% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.